Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

Synthesis and Evaluation of New Naphthalene and Naphthoquinone Derivatives as Anticancer Agents.

Beretta GL, Ribaudo G, Menegazzo I, Supino R, Capranico G, Zunino F, Zagotto G.

Arch Pharm (Weinheim). 2017 Jan;350(1). doi: 10.1002/ardp.201600286. Epub 2016 Dec 19.

PMID:
27990691
2.

TIMP3 regulates migration, invasion and in vivo tumorigenicity of thyroid tumor cells.

Anania MC, Sensi M, Radaelli E, Miranda C, Vizioli MG, Pagliardini S, Favini E, Cleris L, Supino R, Formelli F, Borrello MG, Pierotti MA, Greco A.

Oncogene. 2011 Jul 7;30(27):3011-23. doi: 10.1038/onc.2011.18. Epub 2011 Feb 21.

PMID:
21339735
3.

Phospholipids and a phospholipid-rich diet alter the in vitro amyloid-beta peptide levels and amyloid-beta 42/40 ratios.

Amtul Z, Uhrig M, Supino R, Beyreuther K.

Neurosci Lett. 2010 Sep 6;481(2):73-7. doi: 10.1016/j.neulet.2010.06.046. Epub 2010 Jun 19.

PMID:
20600609
4.

miR-21: an oncomir on strike in prostate cancer.

Folini M, Gandellini P, Longoni N, Profumo V, Callari M, Pennati M, Colecchia M, Supino R, Veneroni S, Salvioni R, Valdagni R, Daidone MG, Zaffaroni N.

Mol Cancer. 2010 Jan 21;9:12. doi: 10.1186/1476-4598-9-12.

5.

Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN.

De Cesare M, Sfondrini L, Campiglio M, Sommariva M, Bianchi F, Perego P, van Rooijen N, Supino R, Rumio C, Zunino F, Pratesi G, Tagliabue E, Balsari A.

J Immunother. 2010 Jan;33(1):8-15. doi: 10.1097/CJI.0b013e3181affaa7.

PMID:
19952960
6.

Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell carcinoma.

Zuco V, Supino R, Favini E, Tortoreto M, Cincinelli R, Croce AC, Bucci F, Pisano C, Zunino F.

Biochem Pharmacol. 2010 Feb 15;79(4):535-41. doi: 10.1016/j.bcp.2009.09.012.

PMID:
19765546
7.

Biological effects of a new vacuolar-H,-ATPase inhibitor in colon carcinoma cell lines.

Supino R, Scovassi AI, Croce AC, Dal Bo L, Favini E, Corbelli A, Farina C, Misiano P, Zunino F.

Ann N Y Acad Sci. 2009 Aug;1171:606-16. doi: 10.1111/j.1749-6632.2009.04705.x.

PMID:
19723111
8.

Gamma-glutamyltransferase-dependent resistance to arsenic trioxide in melanoma cells and cellular sensitization by ascorbic acid.

Giommarelli C, Corti A, Supino R, Favini E, Paolicchi A, Pompella A, Zunino F.

Free Radic Biol Med. 2009 Jun 1;46(11):1516-26. doi: 10.1016/j.freeradbiomed.2009.03.006. Epub 2009 Mar 17.

PMID:
19298852
9.

miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon.

Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M, Salvioni R, Supino R, Moretti R, Limonta P, Valdagni R, Daidone MG, Zaffaroni N.

Cancer Res. 2009 Mar 15;69(6):2287-95. doi: 10.1158/0008-5472.CAN-08-2894. Epub 2009 Feb 24.

10.

Cellular response to oxidative stress and ascorbic acid in melanoma cells overexpressing gamma-glutamyltransferase.

Giommarelli C, Corti A, Supino R, Favini E, Paolicchi A, Pompella A, Zunino F.

Eur J Cancer. 2008 Mar;44(5):750-9. doi: 10.1016/j.ejca.2008.02.010. Epub 2008 Mar 7.

PMID:
18314325
11.

Antimetastatic effect of a small-molecule vacuolar H+-ATPase inhibitor in in vitro and in vivo preclinical studies.

Supino R, Petrangolini G, Pratesi G, Tortoreto M, Favini E, Bo LD, Casalini P, Radaelli E, Croce AC, Bottiroli G, Misiano P, Farina C, Zunino F.

J Pharmacol Exp Ther. 2008 Jan;324(1):15-22. Epub 2007 Oct 1.

PMID:
17909082
12.

Antitumor activity of the combination of synthetic retinoid ST1926 and cisplatin in ovarian carcinoma models.

Pisano C, Vesci L, Foderà R, Ferrara FF, Rossi C, De Cesare M, Zuco V, Pratesi G, Supino R, Zunino F.

Ann Oncol. 2007 Sep;18(9):1500-5. Epub 2007 Aug 13.

PMID:
17698835
13.

Effect of paclitaxel on intracellular localization of c-Myc and P-c-Myc in prostate carcinoma cell lines.

Supino R, Favini E, Cuccuru G, Zunino F, Scovassi AI.

Ann N Y Acad Sci. 2007 Jan;1095:175-81.

PMID:
17404030
14.

Inhibition of c-Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1.

Cassinelli G, Lanzi C, Petrangolini G, Tortoreto M, Pratesi G, Cuccuru G, Laccabue D, Supino R, Belluco S, Favini E, Poletti A, Zunino F.

Mol Cancer Ther. 2006 Sep;5(9):2388-97.

15.

Effect of a novel vacuolar-H+-ATPase inhibitor on cell and tumor response to camptothecins.

Petrangolini G, Supino R, Pratesi G, Dal Bo L, Tortoreto M, Croce AC, Misiano P, Belfiore P, Farina C, Zunino F.

J Pharmacol Exp Ther. 2006 Sep;318(3):939-46. Epub 2006 May 19.

PMID:
16714402
16.

Development of resistance to the atypical retinoid, ST1926, in the lung carcinoma cell line H460 is associated with reduced formation of DNA strand breaks and a defective DNA damage response.

Zuco V, Zanchi C, Lanzi C, Beretta GL, Supino R, Pisano C, Barbarino M, Zanier R, Bucci F, Aulicino C, Carminati P, Zunino F.

Neoplasia. 2005 Jul;7(7):667-77.

17.

Cellular basis of antiproliferative and antitumor activity of the novel camptothecin derivative, gimatecan, in bladder carcinoma models.

Ulivi P, Zoli W, Fabbri F, Brigliadori G, Ricotti L, Tesei A, Rosetti M, De Cesare M, Beretta GL, Corna E, Supino R, Zunino F.

Neoplasia. 2005 Feb;7(2):152-61.

19.

Biocompatibility and tissue interactions of a new filler material for medical use.

Zarini E, Supino R, Pratesi G, Laccabue D, Tortoreto M, Scanziani E, Ghisleni G, Paltrinieri S, Tunesi G, Nava M.

Plast Reconstr Surg. 2004 Sep 15;114(4):934-42.

PMID:
15468401
20.

Role of c-myc protein in hormone refractory prostate carcinoma: cellular response to paclitaxel.

Cassinelli G, Supino R, Zuco V, Lanzi C, Scovassi AI, Semple SC, Zunino F.

Biochem Pharmacol. 2004 Sep 1;68(5):923-31.

PMID:
15294455
21.

Kinetics of novel competitive inhibitors of urease enzymes by a focused library of oxadiazoles/thiadiazoles and triazoles.

Amtul Z, Rasheed M, Choudhary MI, Supino R, Khan KM, Atta-Ur-Rahman.

Biochem Biophys Res Commun. 2004 Jul 2;319(3):1053-63. Erratum in: Biochem Biophys Res Commun. 2004 Nov 19;324(3):1150. Rosanna, Supino [corrected to Supino, Rosanna].

PMID:
15184088
22.

Antitumour and antiangiogenic effects of IDN 5390, a novel C-seco taxane, in a paclitaxel-resistant human ovarian tumour xenograft.

Petrangolini G, Cassinelli G, Pratesi G, Tortoreto M, Favini E, Supino R, Lanzi C, Belluco S, Zunino F.

Br J Cancer. 2004 Apr 5;90(7):1464-8.

23.

Subcellular localization of the camptothecin analogues, topotecan and gimatecan.

Croce AC, Bottiroli G, Supino R, Favini E, Zuco V, Zunino F.

Biochem Pharmacol. 2004 Mar 15;67(6):1035-45.

PMID:
15006540
24.

Induction of apoptosis and stress response in ovarian carcinoma cell lines treated with ST1926, an atypical retinoid.

Zuco V, Zanchi C, Cassinelli G, Lanzi C, Supino R, Pisano C, Zanier R, Giordano V, Garattini E, Zunino F.

Cell Death Differ. 2004 Mar;11(3):280-9.

25.

Antiangiogenic effects of the novel camptothecin ST1481 (gimatecan) in human tumor xenografts.

Petrangolini G, Pratesi G, De Cesare M, Supino R, Pisano C, Marcellini M, Giordano V, Laccabue D, Lanzi C, Zunino F.

Mol Cancer Res. 2003 Oct;1(12):863-70.

26.

Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1.

Lanzi C, Cassinelli G, Cuccuru G, Zaffaroni N, Supino R, Vignati S, Zanchi C, Yamamoto M, Zunino F.

Cell Mol Life Sci. 2003 Jul;60(7):1449-59.

PMID:
12943231
27.

Effect of apoptogenic stimuli on colon carcinoma cell lines with a different c-myc expression level.

Gorrini C, Donzelli M, Torriglia A, Supino R, Brison O, Bernardi R, Negri C, Denegri M, Counis MF, Ranzani GN, Scovassi AI.

Int J Mol Med. 2003 Jun;11(6):737-42.

PMID:
12736715
28.

Cellular bases of the antitumor activity of a 7-substituted camptothecin in hormone-refractory human prostate carcinoma models.

Zuco V, Supino R, De Cesare M, Carenini N, Perego P, Gatti L, Pratesi G, Pisano C, Martinelli R, Bucci F, Zanier R, Carminati P, Zunino F.

Biochem Pharmacol. 2003 Apr 15;65(8):1281-94.

PMID:
12694869
29.

Photosensitizer accumulation in spontaneous multidrug resistant cells: a comparative study with Rhodamine 123, Rose Bengal acetate and Photofrine.

Croce AC, Supino R, Lanza KS, Locatelli D, Baglioni P, Bottiroli G.

Photochem Photobiol Sci. 2002 Jan;1(1):71-8.

PMID:
12659152
30.

IDN 5390: an oral taxane candidate for protracted treatment schedules.

Pratesi G, Laccabue D, Lanzi C, Cassinelli G, Supino R, Zucchetti M, Frapolli R, D'Incalci M, Bombardelli E, Morazzoni P, Riva A, Zunino F.

Br J Cancer. 2003 Mar 24;88(6):965-72.

31.

A novel atypical retinoid endowed with proapoptotic and antitumor activity.

Cincinelli R, Dallavalle S, Merlini L, Penco S, Pisano C, Carminati P, Giannini G, Vesci L, Gaetano C, Illy B, Zuco V, Supino R, Zunino F.

J Med Chem. 2003 Mar 13;46(6):909-12.

PMID:
12620066
32.

Apoptosis and growth arrest induced by platinum compounds in U2-OS cells reflect a specific DNA damage recognition associated with a different p53-mediated response.

Gatti L, Supino R, Perego P, Pavesi R, Caserini C, Carenini N, Righetti SC, Zuco V, Zunino F.

Cell Death Differ. 2002 Dec;9(12):1352-9.

33.

Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer.

Zaffaroni N, Pennati M, Colella G, Perego P, Supino R, Gatti L, Pilotti S, Zunino F, Daidone MG.

Cell Mol Life Sci. 2002 Aug;59(8):1406-12.

PMID:
12363043
34.

Cellular bases of the antitumor activity of the novel taxane IDN 5109 (BAY59-8862) on hormone-refractory prostate cancer.

Cassinelli G, Lanzi C, Supino R, Pratesi G, Zuco V, Laccabue D, Cuccuru G, Bombardelli E, Zunino F.

Clin Cancer Res. 2002 Aug;8(8):2647-54.

35.
37.

Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells.

Zuco V, Supino R, Righetti SC, Cleris L, Marchesi E, Gambacorti-Passerini C, Formelli F.

Cancer Lett. 2002 Jan 10;175(1):17-25.

PMID:
11734332
38.

A role for c-myc in DNA damage-induced apoptosis in a human TP53-mutant small-cell lung cancer cell line.

Supino R, Perego P, Gatti L, Caserini C, Leonetti C, Colantuono M, Zuco V, Carenini N, Zupi G, Zunino F.

Eur J Cancer. 2001 Nov;37(17):2247-56.

PMID:
11677115
39.

A novel 9-aza-anthrapyrazole effective against human prostatic carcinoma xenografts.

Supino R, Polizzi D, Pavesi R, Pratesi G, Guano F, Capranico G, Palumbo M, Sissi C, Richter S, Beggiolin G, Menta E, Pezzoni G, Spinelli S, Torriani D, Carenini N, Dal Bo L, Facchinetti F, Tortoreto M, Zunino F.

Oncology. 2001;61(3):234-42.

PMID:
11574780
40.

Cell cycle checkpoint efficiency and cellular response to paclitaxel in prostate cancer cells.

Lanzi C, Cassinelli G, Cuccuru G, Supino R, Zuco V, Ferlini C, Scambia G, Zunino F.

Prostate. 2001 Sep 15;48(4):254-64.

PMID:
11536305
41.

Nitroxide TEMPOL impairs mitochondrial function and induces apoptosis in HL60 cells.

Monti E, Supino R, Colleoni M, Costa B, Ravizza R, Gariboldi MB.

J Cell Biochem. 2001;82(2):271-6.

PMID:
11527152
42.

Sinusoidal 50 Hz magnetic fields do not affect structural morphology and proliferation of human cells in vitro.

Supino R, Bottone MG, Pellicciari C, Caserini C, Bottiroli G, Belleri M, Veicsteinas A.

Histol Histopathol. 2001 Jul;16(3):719-26. doi: 10.14670/HH-16.719.

PMID:
11510961
43.

A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes.

Cassinelli G, Supino R, Perego P, Polizzi D, Lanzi C, Pratesi G, Zunino F.

Int J Cancer. 2001 Jun 1;92(5):738-47.

44.

Configurational requirements of the sugar moiety for the pharmacological activity of anthracycline disaccharides.

Arcamone F, Animati F, Bigioni M, Capranico G, Caserini C, Cipollone A, De Cesare M, Ettorre A, Guano F, Manzini S, Monteagudo E, Pratesi G, Salvatore C, Supino R, Zunino F.

Biochem Pharmacol. 1999 May 15;57(10):1133-9.

PMID:
11230800
45.

Role of apoptosis and apoptosis-related genes in cellular response and antitumor efficacy of anthracyclines.

Perego P, Corna E, De Cesare M, Gatti L, Polizzi D, Pratesi G, Supino R, Zunino F.

Curr Med Chem. 2001 Jan;8(1):31-7. Review.

PMID:
11172690
46.

The nitroxide tempol induces oxidative stress, p21(WAF1/CIP1), and cell death in HL60 cells.

Gariboldi MB, Rimoldi V, Supino R, Favini E, Monti E.

Free Radic Biol Med. 2000 Oct 1;29(7):633-41.

PMID:
11033415
47.

BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin.

Manzotti C, Pratesi G, Menta E, Di Domenico R, Cavalletti E, Fiebig HH, Kelland LR, Farrell N, Polizzi D, Supino R, Pezzoni G, Zunino F.

Clin Cancer Res. 2000 Jul;6(7):2626-34.

48.

Membrane gamma-glutamyl transpeptidase activity of melanoma cells: effects on cellular H(2)O(2) production, cell surface protein thiol oxidation and NF-kappa B activation status.

Maellaro E, Dominici S, Del Bello B, Valentini MA, Pieri L, Perego P, Supino R, Zunino F, Lorenzini E, Paolicchi A, Comporti M, Pompella A.

J Cell Sci. 2000 Aug;113 ( Pt 15):2671-8.

49.

Telomerase activity and telomere length in human ovarian cancer and melanoma cell lines: correlation with sensitivity to DNA damaging agents.

Villa R, Folini M, Perego P, Supino R, Setti E, Daidone MG, Zunino F, Zaffaroni N.

Int J Oncol. 2000 May;16(5):995-1002.

PMID:
10762636
50.

New 1,4-anthracene-9,10-dione derivatives as potential anticancer agents.

Zagotto G, Supino R, Favini E, Moro S, Palumbo M.

Farmaco. 2000 Jan;55(1):1-5.

PMID:
10755224

Supplemental Content

Loading ...
Support Center